Efficacy and Safety of Liraglutide in Patients With an Ileal Pouch-Anal Anastomosis and Chronic High Bowel Frequency: A Placebo-Controlled, Crossover, Proof-of-Concept Study

What Was Tested

This randomized controlled trial paper looks at Liraglutide.

After colectomy with ileoanal pouch anastomosis (IPAA), many patients develop high bowel frequency (BF) refractory to antimotility agents, despite normal IPAA morphology.

Low circulating levels of glucagon-like protein-1 (GLP-1), a modulator of gastroduodenal motility, have been reported after colectomy.

Who Took Part

According to the abstract, 8 patients were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Double-blind crossover study of 8 IPAA patients with refractory high BF treated with daily administration of the GLP-1 receptor agonist liraglutide or placebo.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Liraglutide and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Liraglutide, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Liraglutide group a baseline to be compared against.

In the crossover set-up each of the patients took both Liraglutide and the comparison in turn, acting as their own control.

What Was Measured

Low circulating levels of glucagon-like protein-1 (GLP-1), a modulator of gastroduodenal motility, have been reported after colectomy.

PubMed files the paper under topics including Colonic Pouches, Liraglutide, Postoperative Complications, Proctocolectomy, Restorative and Proof of Concept Study.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Liraglutide in 8 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 2 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (The American journal of gastroenterology), a journal based in United States.

More context: the Liraglutide compound page.